LifeVantage to Report Q4 & FY25 Results on Sept. 4, 2025

LifeVantage Corporation, a health and wellness company, will announce its Q4 and FY25 financial results on September 4, 2025. The company will hold a conference call at 2:30 p.m. Mountain Time. Investors can dial (877) 704-4453 or (201) 389-0920 to participate. A replay will be available through September 18, 2025. The webcast will be archived for approximately 30 days on the company's website.

Title: LifeVantage Corporation to Announce Q4 and FY25 Financial Results

LifeVantage Corporation (LFVN), a health and wellness company focused on cellular-level health products, will announce its fourth quarter (Q4) and full fiscal year 2025 (FY25) financial results on September 4, 2025. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time). U.S. participants can dial (877) 704-4453, while international callers should use (201) 389-0920. A replay will be available until September 18, 2025. A live webcast will be accessible through the company's Investor Relations website, with a 30-day archive period.

LifeVantage has been actively expanding its product portfolio and market reach. In July 2025, the company announced plans to enter the Iceland market, set to launch in September 2025. This expansion includes a select portfolio of wellness products, including the flagship Protandim Nrf2 Synergizer, MindBody GLP-1 System, TrueScience Liquid Collagen, and LifeVantage ProBio. The company will also introduce its business opportunity through the Evolve Compensation Plan, allowing local entrepreneurs to join as Consultants.

In May 2025, LifeVantage declared a quarterly cash dividend of $0.045 per share of common stock, representing a 12.5% increase from the previous quarter. The dividend will be paid on June 13, 2025, to stockholders of record at the close of business on May 30, 2025.

LifeVantage has also been focusing on clinical studies and product launches. In July 2025, the company announced expanded clinical trial results for its MindBody GLP-1 System™, showing enhanced effectiveness in natural GLP-1 production. The combined data from trials completed in April 2025 and fall 2024 demonstrated an average increase in GLP-1 of over 200%, up from the previously reported 140%. The clinical studies revealed significant outcomes including average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds. Key body composition improvements include up to 9% decrease in total body fat, 24% decrease in visceral fat, and 6% increase in skeletal muscle. Notably, 100% of weight lost was from fat, not muscle. Participants reported substantial behavioral changes, with 95% experiencing decreased sugar cravings and over 85% reporting improved eating habits and reduced hunger.

In March 2025, LifeVantage expanded its MindBody GLP-1 System™ (MB System™) internationally following significant success in the U.S. market. The MB System™ launched on March 15, 2025, in Japan for both Consultants and Customers, while becoming available exclusively to Consultants in Australia, New Zealand, Europe, UK, Mexico, and Thailand, with customer access starting April 25. The product is designed to naturally activate the body's GLP-1 production for metabolic health benefits.

Investors and financial professionals are advised to stay tuned for the Q4 and FY25 financial results announcement to gain insights into the company's performance and future prospects.

References
[1] https://www.stocktitan.net/news/LFVN/
[2] https://www.stocktitan.net/news/LFVN/